Changes to Serum Sample Tube and Processing Methodology Does Not Cause Inter-Individual Variation in Automated Whole Serum N-Glycan Profiling in Health and Disease

Abstract

IntroductionSerum N-glycans have been identified as putative biomarkers for numerous diseases. The impact of different serum sample tubes and processing methods on N-glycan analysis has received relatively little attention. This study aimed to determine the effect of different sample tubes and processing methods on the whole serum N-glycan profile in both health and disease. A secondary objective was to describe a robot automated N-glycan release, labeling and cleanup process for use in a biomarker discovery system.Methods25 patients with active and quiescent inflammatory bowel disease and controls had three different serum sample tubes taken at the same draw. Two different processing methods were used for three types of tube (with and without gel-separation medium). Samples were randomised and processed in a blinded fashion. Whole serum N-glycan release, 2-aminobenzamide labeling and cleanup was automated using a Hamilton Microlab STARlet Liquid Handling robot. Samples were analysed using a hydrophilic interaction liquid chromatography/ethylene bridged hybrid(BEH) column on an ultra-high performance liquid chromatography instrument. Data were analysed quantitatively by pairwise correlation and hierarchical clustering using the area under each chromatogram peak. Qualitatively, a blinded assessor attempted to match chromatograms to each individual.ResultsThere was small intra-individual variation in serum N-glycan profiles from samples collected using different sample processing methods. Intra-individual correlation coefficients were between 0.99 and 1. Unsupervised hierarchical clustering and principal coordinate analyses accurately matched samples from the same individual. Qualitative analysis demonstrated good chromatogram overlay and a blinded assessor was able to accurately match individuals based on chromatogram profile, regardless of disease status.ConclusionsThe three different serum sample tubes processed using the described methods cause minimal inter-individual variation in serum whole N-glycan profile when processed using an automated workstream. This has important implications for N-glycan biomarker discovery studies using different serum processing standard operating procedures.

Serum N-glycome alterations in colorectal cancer associate with survival

“…Both pre-operative as post-operative serum samples from cases had been stored at 20° C after centrifugation until monthly biobank collection and storage at 80° C, while serum samples from controls were stored directly at −80° C after centrifugation. Previously, it has been reported that glycans are not susceptible to changes in tubes used for sample storage or processing methodology [ 41 ]. Our long-term experience with glycan sample storage corroborates with these findings and has not pointed towards any type of glycan degradation during biobanking.…”

Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology

“…IgE samples were dried down before release. PNGase F release of N-glycans (E-PNG01; QA-Bio, http://glycotools.qa-bio.com) was performed in a manner similar to that previously published E4 . In short, 25-μg aliquots of the samples in water (17.5 μL) were incubated with 5 μL of 5× Reaction Buffer 7.5 and 1.25 μL of Denaturation Solution for 10 minutes at 100°C, followed by addition of Triton X-100 (1.25 μL) and PNGase F solution (1 μL) and incubation overnight at 37°C.…”

Interlaboratory evaluation of plasma N-glycan antennary fucosylation as a clinical biomarker for HNF1A-MODY using liquid chromatography methods

“…Enzymatic release and fluorescent labelling of N-glycans from human blood plasma samples were performed using a highly automated analytical workflow for high-throughput (HTP) glycomics supported by a Hamilton STARlet liquid handling robot, as described previously [30,31] with minor modifications. Here, we used 4 µL of human blood plasma samples and a procainamide labelling kit with sodium cyanoborohydride as the reductant (LT-KPROC-96, Ludger) for fluorescent labelling of released N-glycans.…”